NASDAQ:VRMLVermillion Stock Price, Forecast & News

$3.27

+0.02 (+0.62 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$3.15

Now: $3.27▼

$3.47

50-Day Range

$0.90

MA: $1.83▼

$3.25

52-Week Range

$0.35

Now: $3.27▼

$3.47

Volume1.19 million shs

Average Volume499,829 shs

Market Capitalization$318.43 million

P/E RatioN/A

Dividend YieldN/A

Beta3.12

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vermillion.

2.5 Community Rank

Outperform Votes
Vermillion has received 202 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vermillion has received 204 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Vermillion has received 50.25% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote “Outperform” if you believe VRML will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vermillion does not currently pay a dividend.
Dividend Growth
Vermillion does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vermillion insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Vermillion is held by insiders.
Percentage Held by Institutions
Only 18.09% of the stock of Vermillion is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Vermillion is -19.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vermillion is -19.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vermillion has a P/B Ratio of 65.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRML

Previous Symbol

CUSIPN/A

CIK926617

Webwww.vermillion.com

Phone512-519-0400

Debt

Debt-to-Equity Ratio0.20

Current Ratio2.51

Quick Ratio2.49

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.54 million

Price / Sales70.14

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.05 per share

Price / Book65.40

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-15,240,000.00

Net Margins-307.31%

Return on Equity-155.25%

Return on Assets-103.47%

Miscellaneous

Employees43

Outstanding Shares97,380,000

Market Cap$318.43 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive VRML News and Ratings via Email

Sign-up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter.

Vermillion (NASDAQ:VRML) Frequently Asked Questions

How has Vermillion's stock been impacted by COVID-19 (Coronavirus)?

Vermillion's stock was trading at $0.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRML stock has increased by 289.3% and is now trading at $3.27. View which stocks have been most impacted by Coronavirus.

When is Vermillion's next earnings date?

Vermillion is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vermillion.

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) issued its earnings results on Thursday, March, 26th. The company reported ($0.03) EPS for the quarter. The business earned $1.31 million during the quarter. Vermillion had a negative return on equity of 155.25% and a negative net margin of 307.31%. View Vermillion's earnings history.

Has Vermillion been receiving favorable news coverage?

Press coverage about VRML stock has been trending very negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vermillion earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutVermillion.

Are investors shorting Vermillion?

Vermillion saw a drop in short interest in April. As of April 30th, there was short interest totaling 2,200,000 shares, a drop of 18.2% from the April 15th total of 2,690,000 shares. Based on an average daily volume of 163,100 shares, the days-to-cover ratio is currently 13.5 days. Currently, 4.4% of the shares of the stock are sold short. View Vermillion's Current Options Chain.

Who are some of Vermillion's key competitors?

Some companies that are related to Vermillion include Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Arca Biopharma (ABIO), Trinity Biotech (TRIB), GeneNews (GNWSF) and Akers Biosciences (AKER). View all competitors.

What other stocks do shareholders of Vermillion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vermillion investors own include CombiMatrix (CBMX), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Idera Pharmaceuticals (IDRA), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), TrovaGene (TROV), Charter Communications (CHTR), Fluidigm (FLDM) and Magnachip Semiconductor (MX).

Who are Vermillion's key executives?

Vermillion's management team includes the following people:

Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 58)
Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 56)
Mr. Chris Goulart, Sr. VP of Commercial Operations

What is Vermillion's stock symbol?

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

Who are Vermillion's major shareholders?

Vermillion's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Lincoln National Corp (0.20%), BlackRock Inc. (0.14%), Commonwealth Equity Services LLC (0.13%), Oxford Financial Group Ltd. (0.07%), Magnus Financial Group LLC (0.06%) and Trellus Management Company LLC (0.03%). Company insiders that own Vermillion stock include David Schreiber, Jack W Schuler, James T Lafrance, Robert Harry Beechey and Valerie Barber Palmieri. View institutional ownership trends for Vermillion.

Which major investors are selling Vermillion stock?

VRML stock was sold by a variety of institutional investors in the last quarter, including Magnus Financial Group LLC, and Trellus Management Company LLC. View insider buying and selling activity for Vermillion.

Which major investors are buying Vermillion stock?

VRML stock was bought by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Oxford Financial Group Ltd., Lincoln National Corp, Heritage Investors Management Corp, and BlackRock Inc.. Company insiders that have bought Vermillion stock in the last two years include Jack W Schuler, Robert Harry Beechey, and Valerie Barber Palmieri. View insider buying and selling activity for Vermillion.

How do I buy shares of Vermillion?

Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vermillion's stock price today?

One share of VRML stock can currently be purchased for approximately $3.27.

How big of a company is Vermillion?

Vermillion has a market capitalization of $318.43 million and generates $4.54 million in revenue each year. Vermillion employs 43 workers across the globe.

What is Vermillion's official website?

The official website for Vermillion is www.vermillion.com.

How can I contact Vermillion?

Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff